The development and implementation of, and first years' experience with, a massive/emergency transfusion protocol (damage control hematology protocol) in a veterans affairs hospital

Military Medicine

Volumn 179, Issue 10, 2014, Pages 1099-1105

  Gehrie, Eric A ^a,b   Tormey, Christopher A ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; CRYOPRECIPITATE COAGULUM; FIBRINOGEN;

AGED; BLOOD BANK; BLOOD GROUP TYPING; BLOOD TRANSFUSION; CASE REPORT; CLINICAL AUDIT; CLINICAL PROTOCOL; CONNECTICUT; EMERGENCY; ERYTHROCYTE TRANSFUSION; GOVERNMENT; HEMATEMESIS; HOSPITAL LABORATORY; HUMAN; MALE; OPERATIVE BLOOD LOSS; ORGANIZATION AND MANAGEMENT; PLASMA EXCHANGE; POSTOPERATIVE HEMORRHAGE; PROCEDURES; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; THROMBOCYTE TRANSFUSION; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD BANKS; BLOOD GROUPING AND CROSSMATCHING; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CLINICAL AUDIT; CLINICAL PROTOCOLS; CONNECTICUT; EMERGENCIES; ERYTHROCYTE TRANSFUSION; FACTOR VIIA; FACTOR VIII; FIBRINOGEN; HEMATEMESIS; HOSPITALS, VETERANS; HUMANS; LABORATORIES, HOSPITAL; MALE; PLASMA EXCHANGE; PLATELET TRANSFUSION; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 84928501191     PISSN: 00264075     EISSN: 1930613X     Source Type: Journal    
DOI: 10.7205/MILMED-D-14-00045     Document Type: Article

References (30)

1. Kashuk JL, Moore EE, Millikan JS, Moore JB: Major abdominal vascular trauma: a unified approach. J Trauma 1982; 22: 672-679.
2. Young PP, Cotton BA, Goodnough LT: Massive transfusion protocols for patients with substantial hemorrhage. Transfus Med Rev 2011; 25: 293-303.
3. Gonzalez EA, Moore FA, Holcomb JB, et al: Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62: 112-119.
4. Lal DS, Shaz BH: Massive transfusion: blood component ratios. Curr Opin Hematol 2013; 20: 521-525.
5. Holcomb JB, del Junco DJ, Fox EE, et al: The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013; 148: 127-136.
6. Brasel KJ, Vercruysse G, Spinella PC, et al: The association of blood component use ratios with the survival of massively transfused trauma patients with and without severe brain injury. J Trauma 2011; 71: S343-352.
7. Gunter OL Jr, Au BK, Isbell JM, Mowery NT, Young PP, Cotton BA: Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma 2008; 65: 527-534.
8. O'Keeffe T, Refaai M, Tchorz K, Forestner JE, Sarode R: A massive transfusion protocol to decrease blood component use and costs. Arch Surg 2008; 143: 686-690; discussion 690-681.
9. Hirshberg A, Dugas M, Banez EI, Scott BG, Wall MJ Jr, Mattox KL: Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003; 54: 454-463.
10. Cotton BA, Gunter OL, Isbell J, et al: Damage control hematology: the impact of a trauma exsanguination protocol on survival and blood product utilization. J Trauma 2008; 64: 1177-1182; discussion 1182-1173.
11. Holcomb JB, Jenkins D, Rhee P, et al: Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007; 62: 307-310.
12. Dente CJ, Shaz BH, Nicholas JM, et al: Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma 2009; 66: 1616-1624.
13. CRASH-2 Collaborators, Shakur H, Roberts I, et al: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
14. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ: Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) study. Arch Surg 2012; 147: 113-119.
15. Como JJ, Dutton RP, Scalea TM, Edelman BB, Hess JR: Blood transfusion rates in the care of acute trauma. Transfusion 2004; 44: 809-813.
16. Hess JR: Blood and coagulation support in trauma care. Hematology Am Soc Hematol Educ Program 2007: 187-191.
17. Bracey A HC, Weiskopf R, Sipherd B, Steiner EA: Guidelines for Massive Transfusion. AABB. Bethesda, AABB, 2005.
18. Holcomb JB, Zarzabal LA, Michalek JE, et al: Increased platelet: RBC ratios are associated with improved survival after massive transfusion. J Trauma 2011; 71: S318-328.
19. Shaz BH, Dente CJ, Nicholas J, et al: Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion 2010; 50: 493-500.
20. Teixeira PG, Inaba K, Shulman I, et al: Impact of plasma transfusion in massively transfused trauma patients. J Trauma 2009; 66: 693-697.
21. Administration DoVAVH: Transfusion Utilization Committee and Program. VHA Directive 2009-005, 2009. Available at http://www.va.gov/vhapublications/ViewPublication.asp?pub_ID=1827; accessed May 16, 2014.
22. Mamtani R, Nascimento B, Rizoli S, Pinto R, Lin Y, Tien H: The utility of recombinant factor VIIa as a last resort in trauma. World J Emerg Surg 2013; 7 Suppl 1: S7.
23. Lin Y, Stanworth S, Birchall J, Doree C, Hyde C: Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ 2010; 183: E9-19.
24. Knudson MM, Cohen MJ, Reidy R, et al: Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg 2010; 212: 87-95.
25. Ho KM, Litton E: Cost-effectiveness of using recombinant activated factor VII as an off-label rescue treatment for critical bleeding requiring massive transfusion. Transfusion 2012; 52: 1696-1702.
26. Hauser CJ, Boffard K, Dutton R, et al: Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma 2010; 69: 489-500.
27. Dutton RP, Parr M, Tortella BJ, et al: Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma 2011; 71: 12-19.
28. Tormey CA, Fisk J, Stack G: Red blood cell alloantibody frequency, specificity, and properties in a population of male military veterans. Transfusion 2008; 48: 2069-2076.
29. Zink KA, Sambasivan CN, Holcomb JB, Chisholm G, Schreiber MA: A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg 2009; 197: 565-570; discussion 570.
30. Hiippala ST, Myllyla GJ, Vahtera EM: Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-365.